share_log

Ocugen | 8-K: Ocugen Announces U.S. Food and Drug Administration Approval of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

SEC announcement ·  Apr 8 13:17
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more